Saturday, July 11, 2026

pharma · Prostate Cancer · Hot Flush

Astellas Pharma

Astellas Pharma is a pharma organization headquartered in EU. Primary therapeutic focus areas include Prostate Cancer, Hot Flush, Advanced Solid Tumors, Advanced cancer of the stomach or the gastroesophageal junction, Ga

2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, JP HQ
12,378 Employees
EMA registrant Type
Company details
Status
Public
HQ
2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, JP
Employees
12,378
Programs
22
Drugs
52
Patents
25
Clinical program

PMR-EC-1206

Phase 2 · small molecule · Prophylaxis of primary liver, kidney, heart, lung, and intestinal organ transplant rejection

PMR-EC-1206 for Prophylaxis of primary liver, kidney, heart, lung, and intestinal organ transplant rejection is a Phase 2 program (small_molecule) at Astellas Pharma GmbH with 1 ClinicalTrials.gov record(s).

← All Astellas Pharma GmbH projects Phase 2 small molecule active

Internal code PMR-EC-1206

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Astellas Pharma GmbH
Phase
Phase 2
Modality
small_molecule
Indication
Prophylaxis of primary liver, kidney, heart, lung, and intestinal organ transplant rejection
Status
active
Trials
1